New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:20 EDTVRX, AGNAllergan shares set to rise after next Valeant offer, says Bernstein
Bernstein expects Valeant's (VRX) next offer for Allergan (AGN) to be "credible," causing Allergan's stock to rise "at the very least." The firm believes that Allergan and Valeant are currently trading at levels that suggest that there is little chance that a deal will occur, and Bernstein thinks this is an incorrect view of the situation. The firm expects Valeant's next bid to be in the range of $190 per share, and it believes that the next logical step would be for Valeant to offer $190 per share in cash. It keeps an Outperform rating on Allergan.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:29 EDTVRXValeant selected as lead bidder to acquire Dendreon, Provenge for $296M
Subscribe for More Information
05:20 EDTVRXDendreon reaches agreement for Valeant to serve as 'stalking horse bidder'
Subscribe for More Information
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTAGN, VRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use